ATE107176T1 - System zur transdermalen albuterol applikation. - Google Patents

System zur transdermalen albuterol applikation.

Info

Publication number
ATE107176T1
ATE107176T1 AT90123100T AT90123100T ATE107176T1 AT E107176 T1 ATE107176 T1 AT E107176T1 AT 90123100 T AT90123100 T AT 90123100T AT 90123100 T AT90123100 T AT 90123100T AT E107176 T1 ATE107176 T1 AT E107176T1
Authority
AT
Austria
Prior art keywords
patch
application
albuterol
transdermal albuterol
transdermal
Prior art date
Application number
AT90123100T
Other languages
English (en)
Inventor
Bahram Farhadieh
Rajeeve Dattatrey Gokhale
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE107176T1 publication Critical patent/ATE107176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90123100T 1989-12-04 1990-12-03 System zur transdermalen albuterol applikation. ATE107176T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42576689A 1989-12-04 1989-12-04

Publications (1)

Publication Number Publication Date
ATE107176T1 true ATE107176T1 (de) 1994-07-15

Family

ID=23687946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90123100T ATE107176T1 (de) 1989-12-04 1990-12-03 System zur transdermalen albuterol applikation.

Country Status (11)

Country Link
US (2) US5164189A (de)
EP (1) EP0431519B1 (de)
JP (1) JPH07133230A (de)
KR (1) KR910011247A (de)
AT (1) ATE107176T1 (de)
CA (1) CA2031376A1 (de)
DE (1) DE69009946T2 (de)
DK (1) DK0431519T3 (de)
ES (1) ES2055280T3 (de)
IE (1) IE66203B1 (de)
PT (1) PT96059B (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5549924A (en) * 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
WO1997026871A1 (en) * 1996-01-29 1997-07-31 Savor, Evelyn Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9719076D0 (en) * 1997-09-09 1997-11-12 Movevirgo Limited A material for producing a medical dressing and a medical dressing produced using the material
CN100357143C (zh) * 1998-01-20 2007-12-26 易通公司 起步发动机扭矩限制
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
KR100369779B1 (ko) * 1999-07-12 2003-01-29 주식회사 엘지생명과학 교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US20070218087A1 (en) * 2001-12-07 2007-09-20 Norbert Hoenzelaer Method of controlled release of vanillin for nasal and/or pulmonary uptake
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004007693A2 (en) * 2002-07-16 2004-01-22 University Of South Florida Human immunosuppressive protein
EP2316459B1 (de) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
US20040220785A1 (en) * 2003-01-21 2004-11-04 Van Osdol William W. Computational model for transdermal drug delivery
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
EP1663242B1 (de) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8168600B2 (en) * 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5386180B2 (ja) 2006-02-28 2014-01-15 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 真皮細胞のコンパクト凝集のための方法
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
WO2008049123A2 (en) 2006-10-19 2008-04-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
US8163902B2 (en) 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
CA2587805C (en) * 2007-04-25 2014-02-18 The Procter & Gamble Company Improved vitamin d content uniformity in pharmaceutical dosage forms
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2010022196A2 (en) 2008-08-22 2010-02-25 Sanofi-Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
SG2014005318A (en) 2009-01-23 2014-03-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
AU2010270797B2 (en) 2009-07-08 2015-03-19 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
EP2493468A1 (de) 2009-10-30 2012-09-05 Sanofi Aminobenzoesäurederivate zur verwendung bei der behandlung von krankheiten im zusammenhang mit dihydrogenase
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
BR112012014860A2 (pt) 2009-12-23 2016-03-29 Sanofi Sa pró-fármacos de [4 [4-(5-aminometil-2-flúor-fenil)-piperidin-1-il]-(1h-pirrolo-piridin-il)-metanonas e sua síntese
WO2011078984A1 (en) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
EP2560643A1 (de) 2010-04-20 2013-02-27 Institute for OneWorld Health Verbindungen, zusammensetzungen und verfahren mit 1,3,4-oxadiazol-derivaten
US20110288093A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
BR112012027308B1 (pt) 2010-04-24 2021-07-06 Mycovia Pharmaceuticals, Inc. compostos inibidores de metaloenzima e composições compreendendo os mesmos
KR101937495B1 (ko) 2010-07-28 2019-01-10 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
EA024197B1 (ru) 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
WO2012082746A2 (en) 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2678297A2 (de) 2011-02-25 2014-01-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chrysophaentin-analoga als hemmer des ftsz-proteins
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
WO2012177608A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
IN2014DN00288A (de) 2011-06-19 2015-06-05 Viamet Pharmaceuticals Inc
AU2012273007A1 (en) 2011-06-23 2014-01-30 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
MX2014002535A (es) 2011-09-02 2015-07-17 Univ Columbia Inhibidores de camkii, ip3r, calcineurina, p38 y mk2/3 para tratar las alteraciones metabolicas de la obesidad.
US9309273B2 (en) 2011-12-11 2016-04-12 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2013209516A1 (en) 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
CA2865504A1 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
HUE035512T2 (en) * 2012-07-16 2018-05-02 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of tapentadol
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CA2899281C (en) 2013-01-25 2022-05-31 Rigel Pharmaceuticals, Inc. Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
EP2968551B1 (de) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusionsproteine und verfahren dafür
EP3119415A4 (de) 2014-03-07 2017-11-29 The Arizona Board of Regents on behalf of the University of Arizona Gegen natriumkanäle gerichtete nicht-narkotische crmp2-peptide für chronische schmerzen
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
LT3271347T (lt) 2015-03-19 2022-10-10 Mycovia Pharmaceuticals, Inc. Priešgrybeliniai junginiai ir jų gamybos būdai
CA2993661A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
KR20180052755A (ko) 2015-09-18 2018-05-18 브이피에스-3, 인크. 항진균 화합물 및 이의 제조방법
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物
CA3028997A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
ES2985944T3 (es) 2016-06-29 2024-11-07 Halo Life Science Llc Método de preparación de una sal de ellagato de dicolinio de poco olor y otras sales orgánicas de colina de poco olor
US10370367B2 (en) 2016-10-26 2019-08-06 Rigel Pharmaceuticals, Inc. IRAK inhibitors and method for making and using
US10414753B2 (en) 2016-10-26 2019-09-17 Rigel Pharmaceuticals, Inc. Amide compounds and method for making and using
CA3055292A1 (en) 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
CN112368278B (zh) 2018-05-03 2025-06-17 里格尔药品股份有限公司 Rip1抑制性化合物以及制备和使用其的方法
CR20200582A (es) 2018-05-03 2021-04-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
ES2970382T3 (es) 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Método para bloquear o mejorar el síndrome de liberación de citocinas
CN114364674B (zh) 2019-08-30 2025-10-03 里格尔药品股份有限公司 吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
EP4025574B1 (de) 2019-09-06 2025-05-07 Rigel Pharmaceuticals, Inc. Rip1-inhibitorverbindungen und verfahren zu ihrer herstellung und verwendung
US11564930B2 (en) 2019-09-06 2023-01-31 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
AU2020378407B2 (en) 2019-11-07 2024-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
US12459941B2 (en) 2022-03-31 2025-11-04 Rigel Pharmaceuticals, Inc. Tricyclic IRAK inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4136219A (en) * 1973-02-09 1979-01-23 Odam Norman E Method of applying polyurethane paint to vulcanized rubber
US3935329A (en) * 1973-05-09 1976-01-27 Sheller-Globe Corporation Method of manufacturing new paintable rubber products
US4562075A (en) * 1982-05-20 1985-12-31 Nelson Research & Development Co. Penetration enhancers for transdermal drug delivery of systemic agents
DE2751328A1 (de) * 1976-12-21 1978-06-29 Gen Electric Durch ultraschall verbindbare polyphenylenaether-zusammensetzungen
JPS55139449A (en) * 1979-04-18 1980-10-31 Mitsubishi Gas Chem Co Inc Resin composition
DE3010374A1 (de) * 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
JPS5812304B2 (ja) * 1980-09-16 1983-03-07 旭化成株式会社 芳香族ポリエ−テル樹脂組成物
DE3102253A1 (de) * 1981-01-24 1982-09-02 Basf Ag, 6700 Ludwigshafen Thermoplastische formmasse
EP0107660A4 (de) * 1981-02-26 1984-09-11 Gen Electric Polyphenylenätherzusammensetzungen und verfahren.
US4513120A (en) * 1981-03-23 1985-04-23 General Electric Company Polyphenylene ether compositions
JPS57174344A (en) * 1981-04-21 1982-10-27 Mitsubishi Gas Chem Co Inc Impact-resistant polyphenylene ether resin composition
US4360618A (en) * 1981-11-19 1982-11-23 Monsanto Company Low acrylonitrile content styrene-acrylonitrile polymers blended with polyphenylene oxide
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
JPS59204650A (ja) * 1983-05-10 1984-11-20 Japan Synthetic Rubber Co Ltd 熱可塑性樹脂組成物
KR860001431B1 (ko) * 1983-07-01 1986-09-24 닛뽕 고오세이 고무 가부시기 가이샤 열가소성 수지 조성물
NL8303497A (nl) * 1983-10-12 1985-05-01 Gen Electric Voorwerp geheel of gedeeltelijk vervaardigd uit een polymeermengsel en voorzien van een polyurethaanlaklaag of een polyurethaanlijmlaag.
US4578423A (en) * 1983-12-12 1986-03-25 Monsanto Company Polyblends of polyphenylene oxide and styrene-acrylonitrile polymers having broad acrylonitrile compositional distribution
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
DE3347277A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
DE3347278A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
EP0150021A3 (de) * 1984-01-20 1987-07-15 General Electric Company Polyphenylenätherharzzusammensetzungen mit verbessertem Schmelzfliess- und Überzugsvermögen
US4605670A (en) * 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
DE3409079A1 (de) * 1984-03-13 1985-09-19 Bayer Ag, 5090 Leverkusen Medizinische pflaster
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
DE3586707T2 (de) * 1984-10-05 1993-02-11 Hercon Lab System zur transdermalen applikation eines arzneimittels.
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
EP0184910B1 (de) * 1984-11-15 1992-09-30 Hercon Laboratories Corporation Vorrichtung zur kontrollierten Abgabe von Arzneimittelwirkstoffen
CA1272445A (en) * 1985-02-25 1990-08-07 Yie W. Chien Transdermal pharmaceutical absorption dosage unit and process of pharmaceutical administration
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
JPH0747535B2 (ja) * 1985-11-26 1995-05-24 日東電工株式会社 消炎鎮痛用貼付剤
JPS6310716A (ja) * 1986-07-02 1988-01-18 Teijin Ltd β−刺激薬外用剤
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US4820525A (en) * 1987-09-17 1989-04-11 American Home Products Corporation (Del.) Transdermal drug delivery system
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems

Also Published As

Publication number Publication date
EP0431519B1 (de) 1994-06-15
DK0431519T3 (da) 1994-07-04
CA2031376A1 (en) 1991-06-05
DE69009946D1 (de) 1994-07-21
PT96059B (pt) 1998-07-31
JPH07133230A (ja) 1995-05-23
ES2055280T3 (es) 1994-08-16
US5164189A (en) 1992-11-17
US5290561A (en) 1994-03-01
PT96059A (pt) 1991-09-30
DE69009946T2 (de) 1994-11-03
EP0431519A1 (de) 1991-06-12
IE66203B1 (en) 1995-12-13
IE904345A1 (en) 1991-06-05
KR910011247A (ko) 1991-08-07

Similar Documents

Publication Publication Date Title
DE69009946D1 (de) System zur transdermalen Albuterol Applikation.
DE3685895D1 (de) Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
ATE173162T1 (de) Medizinische vorrichtung zur verabreichung von aktivsubstanzen oder arzneistoffen in sehr niedriger dosis, insbesondere von homöopatischen arzneistoffen
WO1987003490A3 (en) Transdermal delivery system
DE3872109D1 (de) Vorrichtung zur transkutanen wirkstoffabgabe mit doppeltem durchgangsverstaerker.
FI905718A0 (fi) Transdermalt medel.
ATE361073T1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
EP0290482A4 (en) Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
TW252919B (de)
PT93191A (pt) Sistema terapeutico para a administracao retardada e controlada transdermica ou transmucosica de substancias activas
ATE204160T1 (de) Formulierung zur inhalativen applikation
DE69401945D1 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE69133123D1 (de) Vorrichtung zur transdermalen abgabe von annähernd gesättigten medikamenten mit erhöhtem medikamentenfluss
EP1561461A3 (de) Klebstoffmasse zur transdermalen Verabreichung von stark weichmachenden Wirkstoffen
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ATE230980T1 (de) Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden
ATE259226T1 (de) Zusammmensetzungen und verfahren zur verminderung der atmungsdepressionen und begleitender nebenmwirkungen von mu-opioid-verbindungen
EP0164998A3 (de) Mittel und Verfahren zur Erhöhung der transdermalen und transmembranen Penetration topischer und systemischer Wirkstoffe
DE3587698D1 (de) Pharmazeutische Präparate.
DE69730988D1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
BR9304431A (pt) Medicamento processo para sua preparaçao e aplicaçao de uma mistura
ATE69724T1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
FR2706255B1 (fr) Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
Garfield et al. Central effects of local anesthetic agents
AU625402B2 (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee